Nuo Therapeutics Inc. (fka NUOTQ)

[errett]

We may face some pressure today from the failure of the ATHX trial using stem cells-----good news is we just lost one competitor it seems for now. I think this news in a sense confirms the validity of our approach with ALDH---an approach that attacks the problem from multiple vectors.

"At 4 weeks, the proportion of responders on MultiStem was significantly greater than placebo but the benefit was offset by declines in a minority of MultiStem-treated patients such that overall benefit at all time points measured was not significant"

This may mean that Multistem is actually making things worse for a subset of patience. I would like to know:

1) how small is the minority
2) how large were the declines in that minority

Pfizer didn't even bother to comment ----taken fron Y board